In a concerning shift, prostate cancer has now surpassed breast cancer as the most commonly diagnosed form of cancer across the United Kingdom. According to a leading charity’s analysis of NHS data, there were 64,425 prostate cancer diagnoses in 2022, compared to 61,640 new breast cancer cases.
The report by Prostate Cancer UK has uncovered stark regional disparities in testing and diagnosis. While 31% of men in Scotland were diagnosed at stage 4, the figure was just 21% in England. Black men also face a higher risk, with one in four expected to be diagnosed with prostate cancer in their lifetime.
“Prostate cancer is now the most common cancer in the UK, but despite this, men are facing deeply unfair inequities across the country, and their experiences vary hugely based on where they live,” said Chiara De Biase, the charity’s director of health services, equity and improvement.
The analysis found that prostate-specific antigen (PSA) testing rates were highest in the South-East of England and lowest in the North-West. Men living in more deprived areas were also 29% more likely to be diagnosed with advanced, harder-to-treat cancer.
Prostate Cancer UK is urgently calling for an early detection programme to address these regional inequities. The charity has highlighted the importance of awareness campaigns, which have encouraged more men to get tested, as well as high-profile figures sharing their personal stories.
However, the UK National Screening Committee has recommended against a widespread prostate cancer screening programme, citing concerns over overdiagnosis. Instead, they propose targeted screening for men with certain genetic risk factors.
The Department of Health and Social Care has acknowledged the need to improve outcomes for men with prostate cancer, particularly in deprived communities. Recent steps include expanding access to life-extending treatments and efforts to reduce cancer waiting times.
As prostate cancer becomes the UK’s most prevalent form of the disease, addressing the stark regional and socioeconomic disparities in testing and diagnosis will be crucial to ensuring equitable care and outcomes for all men.
